PV Bulletin

Parenteral iron-containing medicinal products - referral

PRAC starts review of injectable iron-containing medicines. Review will assess risk of low blood phosphate levels and related bone problems.

Primary source: View

Translated From French

PV Bulletin does not take any responsibility for translation errors or omissions, though it has used the best available translation engine.

PV Impact Brief

Urgency: HighConfidence: high

What changed

A referral procedure concerning parenteral iron-containing medicines has commenced, with a review focused on safety implications such as the risk of low blood phosphate levels.

Why it matters

This referral may lead to updates in labeling and necessary risk management actions for the affected products, impacting patient safety protocols.

Action needed

Monitor for changes in labeling requirements and risk management strategies as a result of the ongoing review by PRAC.

Relevant for
Regulatory Intelligence Lead
Processes impacted
Signal Management
Owner

Regulatory Intelligence Lead

Review cadence

Review in the next regulatory intelligence cycle.

Evidence and confidence

Confidence: highSource updated: Sep 4, 2026

Full briefing

Practical implication

Monitor for changes in labeling requirements and risk management strategies as a result of the ongoing review by PRAC.

The European Medicines Agency (EMA) has initiated a referral under Article 31 of Directive 2001/83/EC regarding parenteral iron-containing medicinal products, associated with low blood phosphate levels and bone issues.

What changed: A referral procedure concerning parenteral iron-containing medicines has commenced, with a review focused on safety implications such as the risk of low blood phosphate levels.

Why it matters: This referral may lead to updates in labeling and necessary risk management actions for the affected products, impacting patient safety protocols.

Practical implication: Monitor for changes in labeling requirements and risk management strategies as a result of the ongoing review by PRAC.

View original source

  • Source: EMA - What's new RSS
  • Published at source: 2026-09-04T00:00:00.000Z
  • Discovered by monitor: 2026-09-04T21:35:10.419Z

Published from the regulator source ingestion pipeline after PV impact triage.

#Safety Signal#Safety Signals#Source-ingestion#Regulator-monitor#European Union#Ema.europa.eu#Translated From French

Related updates for your role

publicFDA · USA · Updated Sep 4, 2026

FDA Grants Accelerated Approval to Etcamah for Advanced Breast Cancer

Urgency: High

Regulatory teams must prepare for updating labeling to include details on the new indication and required diagnostic methods, along with planning for the confirmatory studies mandated by the FDA.

Signal ManagementLabelingRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicMHRA · UK · Updated Sep 4, 2026

Change to the definition of regulated activity with children from 1 September 2026

Urgency: High

Organizations must re-evaluate roles related to children's activities and prepare to request Enhanced DBS checks including access to the Children’s Barred List check starting from 1 September 2026.

Country ComplianceRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicUK Health Security Agency · UK · Updated Sep 7, 2026

Low Flu Vaccination Rates Among Primary School Children

Urgency: High

Parents are reminded to complete and return flu vaccination consent forms promptly as vaccination sessions in schools are set to start this week, aiming for completion by late November.

Signal ManagementPV Quality Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: PV Quality Lead, Medical Safety Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicANSM (France) · France · Updated Sep 7, 2026Translated From French

Recall of Gore Viabahn Endoprosthesis with Bioactive Heparin Coating

Urgency: High

Health establishments receiving affected devices must be notified, and protocols established to ensure compliance with the recall.

Signal ManagementQPPV
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: QPPV, Medical Safety Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward